The launch of several novel therapies and multiple label expansions of premium-priced agents will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) therapy market over the ten-year forecast period. Key therapies expected to fuel growth are the recently approved CAR T-cell therapies Yescarta (Gilead / Kite), Kymriah (Novartis), and Tecartus (Gilead / Kite), as well as novel, targeted agents Polivy (Roche) and Monjuvi (MorphoSys / Incyte). In addition, combinations incorporating the BTK inhibitors Imbruvica (Janssen) and Calquence (Acerta / AstraZeneca), the Bcl-2 inhibitor Venclexta / Venclyxto (AbbVie / Roche), and anti-CD20 monoclonal antibodies will enter the market, which will result in a shift away from conventional immunochemotherapy regimens. Notably, the anticipated launch of the novel emerging therapies (bispecific antibody glofitamab (Roche), anti-CD19 ADC loncastuximab tesirine (ADC Therapeutics), anti-CD30 ADC Adcetris (Takeda / Seattle Genetics), and selective inhibitor of nuclear export Xpovio (Karyopharm) will further fragment the R/R DLBCL patient setting and create intense competition. Offsetting this market growth will be the biosimilar erosion expected for rituximab IV and SC, as well as the generic erosion of Celgene’s Revlimid and Janssen's Imbruvica. Untapped clinical and commercial potential remains in NHL for therapies with improved efficacy and for agents positioned in underserved patient segments.

Questions Answered:

  • Which emerging therapies are the most promising in NHL, and what patient populations will they target? What will be their impact on the NHL market?
  • How will market share for rituximab change over the ten-year forecast period as a result of biosimilar entry? Will Roche / Genentech’s Gazyva / Gazyvaro and Rituxan Hycela / MabThera SC be able to minimize the impact of biosimilar erosion of branded rituximab?
  • The NHL therapy market will experience robust growth through 2029. What factors are driving growth in the NHL market? Which drug class will dominate the treatment of NHL? What new classes of agents will emerge over the ten-year forecast period, and what will be their market impact?

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Scope:

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 19 country-specific interviews with experts and 210 country-specific surveys with hematologist-oncologists treating NHL.

Epidemiology: Diagnosed incidence of follicular lymphoma (FL) (including transformed FL), chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma (MCL).

Population segments in market forecast: First-line, second-line, third-line, and fourth-line for FL, CLL / SLL, DLBCL, and MCL.

Emerging therapies: Phase I/II: 19 drugs; Phase III / PR: 9 drugs.

Table of contents

  • Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Landscape & Forecast - Disease Landscape & Forecast
    • Key Updates
      • Q1 2021
        • March 2021
        • February 2021
        • January 2021
      • Q4 2020
        • December 2020
      • Q3 2020
        • September 2020
      • Q2 2020
        • May 2020
      • Q1 2020
        • March 2020
    • Key Findings
      • Non-Hodgkin's Lymphoma - Key Findings
        • March 2020
    • Market Outlook
      • Key Findings
        • Market Share of Drug Classes for Non-Hodgkin's Lymphoma in 2019
        • Market Share of Drug Classes for Non-Hodgkin's Lymphoma in 2029
        • Positioning of Key Therapies in Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma in the United States: 2019-2029
        • Positioning of Key Therapies in Diffuse Large B-Cell Lymphoma in the United States: 2019-2029
        • Positioning of Key Therapies in Follicular Lymphoma in the United States: 2019-2029
        • Positioning of Key Therapies in Mantle Cell Lymphoma in the United States: 2019-2029
        • Non-Hodgkin's Lymphoma SWOT Analysis
        • Current Therapies with Sales Potential in Non-Hodgkin's Lymphoma: Population Positioning
        • Emerging Therapies with Sales Potential in Non-Hodgkin's Lymphoma: Population Positioning
      • COVID-19: Areas of Potential Forecast Impact
        • COVID-19: Areas of Potential Forecast Impact
        • Expert Insights: COVID-19 Impact
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for NHL?
        • What Factors Are Constraining the Market for NHL?
        • Drug-Treatable Population Share and Major-Market Sales Share for CLL / SLL: 2019
        • Drug-Treatable Population Share and Major-Market Sales Share for CLL / SLL: 2029
        • Drug-Treatable Population Share and Major-Market Sales Share for DLBCL: 2019
        • Drug-Treatable Population Share and Major-Market Sales Share for DLBCL: 2029
        • Drug-Treatable Population Share and Major-Market Sales Share for FL: 2019
        • Drug-Treatable Population Share and Major-Market Sales Share for FL: 2029
        • Drug-Treatable Population Share and Major-Market Sales Share for MCL: 2019
        • Drug-Treatable Population Share and Major-Market Sales Share for MCL: 2029
        • Major-Market Non-Hodgkin's Lymphoma Sales by Subpopulation: 2019-2029
        • Key Non-Hodgkin's Lymphoma Therapies with Major-Market Sales Exceeding $1.0 Billion in 2029
      • Segment-Specific Trends
        • Patient-Share Dynamics of Key Drug Classes in First-Line CLL / SLL in the United States: 2019-2029
        • Patient-Share Dynamics of Key Therapies in First-Line CLL / SLL in the United States: 2019-2029
        • Sales of Key Therapies for First-Line CLL / SLL in the United States: 2019-2029
        • Patient-Share Dynamics of Key Therapies in Second-Line CLL / SLL in the United States: 2019-2029
        • Patient-Share Dynamics of Key Therapies in Third-Line CLL / SLL in the United States: 2019-2029
        • Sales of Key Therapies for Second-Line CLL / SLL in the United States: 2019-2029
        • Sales of Key Therapies for Third-Line CLL / SLL in the United States: 2019-2029
        • Patient-Share Dynamics of Key Therapies in First-Line DLBCL in the United States: 2019-2029
        • Sales of Key Therapies for First-Line DLBCL in the United States: 2019-2029
        • Patient-Share Dynamics of Key Therapies in Second-Line DLBCL in the United States: 2019-2029
        • Patient-Share Dynamics of Key Therapies in Third-Line DLBCL in the United States: 2019-2029
        • Sales of Key Therapies for Second-Line DLBCL in the United States: 2019-2029
        • Sales of Key Therapies for Third-Line DLBCL in the United States: 2019-2029
        • Patient-Share Dynamics of Key Therapies in First-Line FL in the United States: 2019-2029
        • Sales of Key Therapies for First-Line FL in the United States: 2019-2029
        • Patient-Share Dynamics of Key Therapies in Second-Line FL in the United States: 2019-2029
        • Patient-Share Dynamics of Key Therapies in Third-Line FL in the United States: 2019-2029
        • Sales of Key Therapies for Second-Line FL in the United States: 2019-2029
        • Sales of Key Therapies for Third-Line FL in the United States: 2019-2029
        • Patient-Share Dynamics of Key Therapies in First-Line MCL in the United States: 2019-2029
        • Sales of Key Therapies for First-Line MCL in the United States: 2019-2029
        • Patient-Share Dynamics of Key Therapies in Second-Line MCL in the United States: 2019-2029
        • Patient-Share Dynamics of Key Therapies in Third-Line MCL in the United States: 2019-2029
        • Sales of Key Therapies for Second-Line MCL in the United States: 2019-2029
        • Sales of Key Therapies for Third-Line MCL in the United States: 2019-2029
    • Forecast
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Disease Overview
        • Disease Pathophysiology
          • Select Risk Factors Associated with Non-Hodgkin's Lymphoma
          • International Prognostic Index Scoring for Patients of All Ages
          • Revised International Prognostic Index Score in Patients Treated with R-CHOP
          • Select Biomarkers for Non-Hodgkin's Lymphoma Subpopulations Predicting Clinical Outcome
        • Staging and Classification
          • Staging of Non-Hodgkin's Lymphoma
          • Revised Ann Arbor Staging System for Primary Nodal Lymphomas
          • The Binet Staging System for CLL / SLL
          • The Rai Staging System for CLL / SLL
          • Normal B-Cell Development and Cellular Origin of B-Cell Malignancies
        • Key Pathways and Drug Targets
          • Key Drug Targets for Non-Hodgkin's Lymphoma
      • Epidemiology
        • Key Findings
          • Epidemiology Populations
            • Disease Definition
            • Methods
            • Sources Used for Diagnosed Incidence of NHL
            • Number of Diagnosed Incident Cases of NHL in the Major Pharmaceutical Markets by Subtype: 2019-2029
            • Disease Definition
            • Methods
            • Sources Used for Molecular Subtype of De Novo DLBCL Incident Cases
            • Number of Diagnosed Incident Cases of De Novo DLBCL in the Major Pharmaceutical Markets by Molecular Subtype: 2019-2029
            • Definition
            • Methods
            • Sources Used for Transformed Incidence from FL to DLBCL
            • Number of Diagnosed Incident Cases of Transformed Incidence from FL to DLBCL in the Major Pharmaceutical Markets: 2019-2029
            • Definition
            • Methods
            • Sources Used for Transformed Incidence from CLL to DLBCL
            • Number of Diagnosed Incident Cases of Transformed Incidence from CLL to DLBCL in the Major Pharmaceutical Markets: 2019-2029
            • FL Patient Flow
            • Number of Drug-Treatable Cases of FL in the Major Pharmaceutical Markets by Line: 2019-2029
            • DLBCL Drug-Treatable Population
            • DLBCL Patient Flow
            • Number of Drug-Treatable Cases of DLBCL in the Major Pharmaceutical Markets by Line: 2019-2029
            • MCL Drug-Treatable Population
            • MCL Patient Flow
            • Number of Drug-Treatable Cases of MCL in the Major Pharmaceutical Markets by Line: 2019-2029
            • CLL / SLL Drug-Treatable Population
            • CLL / SLL Patient Flow
            • Number of Drug-Treatable Cases of CLL / SLL in the Major Pharmaceutical Markets by Line: 2019-2029
            • Number of Drug-Treated Cases of FL in the Major Pharmaceutical Markets by Line: 2019-2029
            • Number of Drug-Treated Cases of DLBCL in the Major Pharmaceutical Markets by Line: 2019-2029
            • Number of Drug-Treated Cases of MCL in the Major Pharmaceutical Markets by Line: 2019-2029
            • Number of Drug-Treated Cases of CLL / SLL in the Major Pharmaceutical Markets by Line: 2019-2029
        • Current Treatment
          • Key Findings
            • Treatment Goals
              • Key Endpoints Used in Clinical Trials for NHL
            • Key Current Therapies
              • Overview
              • Mechanism of Action of Key Current Drug Classes Used for NHL
              • Current Treatments Used for NHL
              • Market Events Impacting the Use of Key Current Therapies in NHL
              • Advantages and Disadvantages of Rituximab (Rituxan / MabThera)
              • Ongoing Clinical Development of Rituximab (Rituxan / MabThera)
              • Key Ongoing Clinical Trials of Rituximab (Rituxan / MabThera) in the Treatment of NHL
              • Expert Insight: Rituximab (Rituxan / MabThera)
              • Advantages and Disadvantages of Gazyva / Gazyvaro
              • Key Results from Select Clinical Trials Investigating Gazyva / Gazyvaro for the Treatment of NHL
              • Ongoing Clinical Development of Gazyva / Gazyvaro
              • Key Ongoing Clinical Trials of Gazyva / Gazyvaro in the Treatment of NHL
              • Expert Insight: Gazyva / Gazyvaro
              • Key Results from Select Clinical Trials Investigating Monjuvi for the Treatment of NHL
              • Ongoing Clinical Development of Monjuvi
              • Key Ongoing Clinical Trials of Monjuvi in the Treatment of NHL
              • Expert Insight: Monjuvi
              • Advantages and Disadvantages of Arzerra
              • Ongoing Clinical Development of Arzerra
              • Expert Insight: Arzerra
              • Advantages and Disadvantages of Campath / MabCampath
              • Advantages and Disadvantages of Polivy
              • Key Results from Select Clinical Trials Investigating Polivy for the Treatment of NHL
              • Analysis of the Clinical Development Program for Polivy
              • Key Ongoing Clinical Trials of Polivy in the Treatment of NHL
              • Expert Insight: Polivy
              • Advantages and Disadvantages of Venclexta / Venclyxto
              • Key Results from Select Clinical Trials Investigating Venclexta / Venclyxto for the Treatment of NHL
              • Ongoing Clinical Development of Venclexta / Venclyxto
              • Key Ongoing Clinical Trials of Venclexta / Venclyxto in the Treatment of NHL
              • Expert Insight: Venclexta / Venclyxto
              • Advantages and Disadvantages of Revlimid (Lenalidomide)
              • Key Results from Select Clinical Trials Investigating Revlimid (Lenalidomide) for the Treatment of NHL
              • Ongoing Clinical Development of Revlimid (Lenalidomide)
              • Key Ongoing Phase III Clinical Trials of Revlimid (Lenalidomide) in the Treatment of NHL
              • Advantages and Disadvantages of Velcade
              • Expert Insight: Velcade
              • Advantages and Disadvantages of Torisel
              • Advantages and Disadvantages of Imbruvica
              • Key Results from Select Clinical Trials Investigating Imbruvica for the Treatment of NHL
              • Key Ongoing Phase III Clinical Trials of Imbruvica in the Treatment of NHL
              • Expert Insight: Imbruvica
              • Advantages and Disadvantages of Calquence
              • Key Results from Select Clinical Trials Investigating Calquence for the Treatment of NHL
              • Ongoing Clinical Development of Calquence
              • Key Ongoing Clinical Trials of Calquence in the Treatment of NHL
              • Expert Insight: Calquence
              • Key Results from Select Clinical Trials Investigating Brukinsa for the Treatment of NHL
              • Key Ongoing Clinical Trials of Brukinsa in the Treatment of NHL
              • Analysis of the Clinical Development Program for Brukinsa
              • Expert Insight: Brukinsa
              • Advantages and Disadvantages of Zydelig
              • Key Results from Select Clinical Trials Investigating Zydelig for the Treatment of NHL
              • Ongoing Clinical Development of Zydelig
              • Key Ongoing Clinical Trials of Zydelig in the Treatment of NHL
              • Expert Insight: Zydelig
              • Advantages and Disadvantages of Aliqopa
              • Key Results from Select Clinical Trials Investigating Aliqopa for the Treatment of NHL
              • Ongoing Clinical Development of Aliqopa
              • Key Ongoing Clinical Trials of Aliqopa in the Treatment of NHL
              • Expert Insight: Aliqopa
              • Advantages and Disadvantages of Copiktra
              • Key Results from Select Clinical Trials Investigating Copiktra for the Treatment of NHL
              • Ongoing Clinical Development of Copiktra
              • Key Ongoing Clinical Trials of Copiktra in the Treatment of NHL
              • Expert Insight: Copiktra
              • Key Results from Select Clinical Trials Investigating Ukoniq for the Treatment of NHL
              • Ongoing Clinical Development of Ukoniq
              • Key Ongoing Clinical Trials of Ukoniq in the Treatment of NHL
              • Expert Insight: Ukoniq
              • Advantages and Disadvantages of Bendamustine
              • Expert Insight: Bendamustine
              • Advantages and Disadvantages of Pixuvri
              • Clinical Development of Pixuvri
              • COVID-19: Areas of Potential Impact on CAR T-Cell Therapy
              • Advantages and Disadvantages of Yescarta
              • Key Results from Select Clinical Trials Investigating Yescarta for the Treatment of NHL
              • Ongoing Clinical Development of Yescarta
              • Key Ongoing Clinical Trials of Yescarta in the Treatment of NHL
              • Expert Insight: Yescarta
              • Advantages and Disadvantages of Kymriah
              • Key Results from Select Clinical Trials Investigating Kymriah for the Treatment of NHL
              • Ongoing Clinical Development of Kymriah
              • Key Ongoing Clinical Trials of Kymriah in the Treatment of NHL
              • Expert Insight: Kymriah
              • Tecartus
              • Key Results from Select Clinical Trials Investigating Tecartus for the Treatment of NHL
              • Ongoing Clinical Development of Tecartus
              • Key Ongoing Clinical Trials of Tecartus in the Treatment of NHL
              • Expert Insight: Tecartus
              • Key Results from Select Clinical Trials Investigating Breyanzi for the Treatment of NHL
              • Ongoing Clinical Development of Breyanzi
              • Key Ongoing Clinical Trials of Breyanzi in the Treatment of NHL
              • Expert Insight: Breyanzi
              • Advantages and Disadvantages of Keytruda
              • Key Results from Select Clinical Trials Investigating Keytruda for the Treatment of NHL
              • Ongoing Clinical Development of Keytruda
              • Key Ongoing Clinical Trials of Keytruda in the Treatment of NHL
              • Expert Insight: Keytruda
              • Tazverik
              • Key Results from Select Clinical Trials Investigating Tazverik for the Treatment of NHL
              • Ongoing Clinical Development of Tazverik
              • Key Ongoing Clinical Trials of Tazverik in the Treatment of NHL
              • Expert Insight: Tazverik
              • Key Results from Select Clinical Trials Investigating Xpovio for the Treatment of NHL
              • Ongoing Clinical Development of Xpovio
              • Key Ongoing Clinical Trials of Xpovio in the Treatment of NHL
              • Expert Insight: Xpovio
            • Medical Practice
              • First-Line CLL / SLL Drug-Treatable Population
              • First-Line DLBCL Drug-Treatable Population
              • First-Line FL Drug-Treatable Population
              • First-Line MCL Drug-Treatable Population
              • Relapsed / Refractory CLL / SLL Drug-Treatable Population
              • Relapsed / Refractory DLBCL Drug-Treatable Population
              • Relapsed / Refractory FL Drug-Treatable Population
              • Relapsed / Refractory MCL Drug-Treatable Population
              • NHL Treatment Guidelines by Market
              • Patient Characteristics Influencing Drug Selection in NHL
              • Treatment Decision Tree for Follicular Lymphoma: United States
              • Treatment Decision Tree for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: United States
              • Treatment Decision Tree for Diffuse Large B-Cell Lymphoma: United States
              • Treatment Decision Tree for Mantle Cell Lymphoma: United States
              • Treatment Decision Tree for Follicular Lymphoma: Europe
              • Treatment Decision Tree for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Europe
              • Treatment Decision Tree for Diffuse Large B-Cell Lymphoma: Europe
              • Treatment Decision Tree for Mantle Cell Lymphoma: Europe
              • Treatment Decision Tree for Follicular Lymphoma: Japan
              • Treatment Decision Tree for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Japan
              • Treatment Decision Tree for Diffuse Large B-Cell Lymphoma: Japan
              • Treatment Decision Tree for Mantle Cell Lymphoma: Japan
          • Unmet Need Overview
            • Current and Future Attainment of Unmet Needs in Non-Hodgkin's Lymphoma
            • Top Unmet Needs in Non-Hodgkin's Lymphoma: Current and Future Attainment
            • Expert Insight: Unmet Need in Non-Hodgkin's Lymphoma
          • Emerging Therapies
            • Key Findings
              • Pipeline Trends in Non-Hodgkin's Lymphoma
            • Key Emerging Therapies
              • Notable Developments Among Key Emerging Therapies for NHL
              • Key Therapies in Development for NHL
              • Estimated Market Authorization Dates of Key Emerging Therapies for the Treatment of NHL
              • Key Results from Select Clinical Trials Investigating Enzastaurin for the Treatment of NHL
              • Key Ongoing Clinical Trials of Enzastaurin in the Treatment of NHL
              • Analysis of the Clinical Development Program for Enzastaurin
              • Expert Insight: Enzastaurin
              • Expectations for Market Authorization and Sales Opportunity of Enzastaurin in NHL
              • Key Results from Select Clinical Trials Investigating Ublituximab for the Treatment of NHL
              • Key Ongoing Clinical Trials of Ublituximab in the Treatment of NHL
              • Analysis of the Clinical Development Program for Ublituximab
              • Expert Insight: Ublituximab
              • Expectations for Market Authorization and Sales Opportunity of Ublituximab in NHL
              • Key Results from Select Clinical Trials Investigating Glofitamab for the Treatment of NHL
              • Key Ongoing Clinical Trials of Glofitamab in the Treatment of NHL
              • Analysis of the Clinical Development Program for Glofitamab
              • Expert Insight: Glofitamab
              • Expectations for Market Authorization and Sales Opportunity of Glofitamab in NHL
              • Key Results from Select Clinical Trials Investigating Blincyto for the Treatment of NHL
              • Key Ongoing Clinical Trials of Blincyto in the Treatment of NHL
              • Analysis of the Clinical Development Program for Blincyto
              • Expert Insight: Blincyto
              • Expectations for Market Authorization and Sales Opportunity of Blincyto in NHL
              • Key Results from Select Clinical Trials Investigating Loncastuximab Tesirine for the Treatment of NHL
              • Key Ongoing Clinical Trials of Loncastuximab Tesirine in the Treatment of NHL
              • Analysis of the Clinical Development Program for Loncastuximab Tesirine
              • Expert Insight: Loncastuximab Tesirine (ADCT-402)
              • Expectations for Market Authorization and Sales Opportunity of Loncastuximab Tesirine in NHL
              • Key Results from Select Clinical Trials Investigating Adcetris for the Treatment of NHL
              • Key Ongoing Clinical Trials of Adcetris in the Treatment of NHL
              • Analysis of the Clinical Development Program for Adcetris
              • Expert Insight: Adcetris
              • Expectations for Market Authorization and Sales Opportunity of Adcetris in NHL
              • Key Results from Select Clinical Trials Investigating Opdivo for the Treatment of NHL
              • Key Ongoing Clinical Trials of Opdivo in the Treatment of NHL
              • Analysis of the Clinical Development Program for Opdivo
              • Expert Insight: Opdivo
              • Expectations for Market Authorization and Sales Opportunity of Opdivo in NHL
            • Early-Phase Pipeline Analysis
              • Select Compounds in Early-Phase Development for NHL
          • Access & Reimbursement Overview
            • Region-Specific Reimbursement Practices
              • Key Market Access Considerations in NHL: United States
              • General Reimbursement Environment: United States
              • Key Market Access Considerations in NHL: EU5
              • General Reimbursement Environment: EU5
              • Key Market Access Considerations in NHL: Japan
              • General Reimbursement Environment: Japan
          • Appendix
            • Key Abbreviations Related to NHL
            • Brands, Marketers, and Generic Availability of Current Therapies Used for NHL by Market
            • Non-Hodgkin's Lymphoma Bibliography

        Author(s): Paul Wilcock, Ph.D.; Arman Esfandiari, M.Res., Ph.D.; Sorcha Cassidy, M.Res., Ph.D.; Vandana, M.Pharm.

        Paul Wilcock, Ph.D., is a senior analyst on the Oncology team at DRG, part of Clarivate. He has authored content on gastroesophageal cancer, multiple myeloma, breast cancer, hepatocellular carcinoma, renal cell carcinoma, as well as the treatment of malignant melanoma and breast cancer with Keytruda/Opdivo and Ibrance, respectively. In addition, he has written multi-indication reports such as the Real World Brand Tracker Summary and an Immune Checkpoint Inhibitor Special Topics report and has published oncology market assessment articles in Nature Reviews Drug Discovery. Previously, Dr. Wilcock was a research funding manager at Cancer Research UK, where he developed a deep understanding of drug discovery, predominantly in the academic setting. He received his doctorate from the University of Manchester, where he used systems biology to explore the role of cell signaling and hypoxia in oral cancer.

        Arman Esfandiari, M.Res., Ph.D., is an analyst on the Oncology and Biosimilars teams at Clarivate. He has a long-standing interest in cancer therapeutics and holds a Ph.D. in cancer biology from Newcastle University. As a postdoctoral research fellow at the Northern Institute for Cancer Research and at University College London, he focused on the research and development of small-molecule inhibitors, DNA-damaging agents, and antibody-drug conjugates. 

        Sorcha Cassidy, M.Res., Ph.D., is an associate director on the Oncology team at DRG, part of Clarivate. She manages a team of analysts who produce syndicated primary and secondary market research reports and custom analysis on a wide range of oncology indications. Dr. Cassidy also provides client support for all oncology products and has expertise in hematologic malignancies and CAR T-cell therapies. She has published oncology market assessment articles in Nature Reviews Drug Discovery. Prior to joining DRG, Dr. Cassidy was a market research manager at Janssen UK. She obtained her M.Res. and Ph.D. in immunology from Imperial College London, where she investigated the role of innate immune modulators (killer immunoglobulin-like receptors [KIRs]) on natural killer cells in various diseases.

        Vandana Singh, M.Pharm., is an associate analyst on the Oncology team at DRG, part of Clarivate. Prior to joining DRG, she was a business analyst in digital marketing at Iquanti in Bangalore. She also conducted competitive intelligence, forecasting, and pipeline analysis at WNS in Noida. She obtained her master’s degree in pharmacology from the University of Delhi.


        Related Reports

        Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Epidemiology - Incyte Proprietary Content

        In this project, commissioned by Incyte in February, 2021, we have packaged our published estimates on the epidemiology of NHL & CLL across all the countries in Europe for which we have coverag...

        View Details

        Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Epidemiology - Janssen Proprietary Content

        In this project, comissioned by Janssen in December, 2018, we have packaged our published estimates on the epidemiology of CLL - drug treated population across all the countries in Latin Ameri...

        View Details

        Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Geographic Focus: China - China In-Depth | China

        Among the four subtypes of non-Hodgkin’s lymphoma (NHL), diffuse large B-cell lymphoma DLBCL is the most common in China. Rituximab (Roche’s MabThera, biosimilars) continues to dominate...

        View Details